Working… Menu

Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04373044
Recruitment Status : Terminated (The study was terminated after the release of results of ACTT-2 (NCT04401579).)
First Posted : May 4, 2020
Last Update Posted : May 26, 2021
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Southern California

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : May 12, 2021
Actual Study Completion Date : May 12, 2021